Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01205230 · ClinicalTrials.gov registry record · Phase 4
VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT01205230 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 34 participants.
The verdict
NCT01205230, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how dosing with ketoconazole (Nizoral) or esomeprazole (Nexium) affects the pharmacokinetics of oral pazopanib. The study will also test for safety of pazopanib when administered with ketoconazole or esomeprazole.
Interventions
- DRUG pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01205230
The ClinicalTrials.gov registry entry for NCT01205230 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pazopanib is the first listed.
NCT01205230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01205230 about?
NCT01205230 is a clinical study titled "VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK". The purpose of this study is to determine how dosing with ketoconazole (Nizoral) or esomeprazole (Nexium) affects the pharmacokinetics of oral pazopanib. The study will also test for safety of pazopanib when administered with ketoconazole or esomeprazole.
What is the current status of trial NCT01205230?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2010-09. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01205230?
The interventions under investigation include: pazopanib (DRUG).
Who is sponsoring clinical trial NCT01205230?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.